Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA

• Treatment of Pyoderma Gangrenosum With Vilobelimab

Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9

• Prevention of Psoriatic Arthritis | RheumNow

Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. https://t.co/9twSiXYL3N https://t.co/9vz77SrVLt

• Digital Rheumatology | RheumNow

Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women Dr. Janet Pope discusses abstract POS0583 presented at Eular 2024 in Vienna, Austria. https://t.co/HIXV4EUkJb https://t.co/p38e6pzAvC

• Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women | Rheu…

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis https://t.co/QKXUxyhPUd https://t.co/Lx0VrBGqtg

• Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis | RheumNow

No Risk of Interstitial Lung Disease with Methotrexate Use JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM). https://t.co/MslJk5TARw https://t.co/BUUiqC8jaQ

• No Risk of Interstitial Lung Disease with Methotrexate Use | RheumNow

TARGET compared triple DMARD to TNFi in 122 RA pts and association with CV risk. In a subanalysis they found no correlation between change in lipid measurements and change in vascular inflammation by FDG-PET. https://t.co/0HKogmdRGH https://t.co/cD7UVTgTQ3

• Impact of RA treatment strategies on lipids and vascular inflammation in rheuma…

Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs

• Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systema…

Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc

• Association of ankylosing spondylitis with the risk of cancer: a meta- analysis…

ChatGPT in Rheumatology and Qualitative Research Dr. Bella Mehta discusses abstract OP0158 presented at Eular 2024 in Vienna, Austria. https://t.co/2EGLJdK2Pl https://t.co/AaRFqyo6jq

• ChatGPT in Rheumatology and Qualitative Research | RheumNow

New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

• New indications for JAK inhibitors | RheumNow